What is the safest way to taper and discontinue alprazolam (2.5 mg nightly) for insomnia in a 76‑year‑old woman who has previously tried trazodone and mirtazapine?

Tapering Alprazolam 2.5 mg in a 76‑Year‑Old Woman

Discontinue alprazolam using a slow, gradual taper of 10% of the current dose per month while simultaneously initiating Cognitive Behavioral Therapy for Insomnia (CBT‑I) and considering low‑dose doxepin 3–6 mg as a safer alternative hypnotic. 1

---

Critical Safety Framework

• Abrupt discontinuation of alprazolam can cause seizures and death—never stop suddenly. 1, 2 The FDA label explicitly warns that withdrawal seizures occur upon rapid decrease or abrupt discontinuation. 2

• Alprazolam carries particularly high withdrawal risk because it is a short‑acting, high‑potency benzodiazepine; withdrawal symptoms peak within 1–2 days after discontinuation and include anxiety, tremor, insomnia, sweating, tachycardia, headache, confusion, and seizures. 1

• At 76 years old, this patient faces compounded risks: benzodiazepines in elderly patients are associated with cognitive impairment, falls, fractures, loss of functional independence, and observational data link prolonged use to increased dementia risk. 1, 3

---

Recommended Tapering Protocol

Month‑by‑Month Taper Schedule

• Start by reducing the dose by 10% of the current dose per month (not 10% of the original dose), which prevents disproportionately large final reductions. 1

• Month 1: Reduce from 2.5 mg/day to 2.25 mg/day (10% reduction). 1

• Month 2: Reduce to 2.0 mg/day (10% of 2.25 mg). 1

• Month 3: Reduce to 1.8 mg/day (10% of 2.0 mg). 1

• Continue this pattern until the smallest available dose is reached, then extend the interval between doses before complete discontinuation. 1

• The taper will likely require a minimum of 12–18 months for a patient on this dose for an extended period; some patients may need several years. 1

Adjusting the Taper Rate

• The taper rate must be determined by the patient's tolerance, not a rigid schedule; pauses of 2–4 weeks are acceptable and often necessary when withdrawal symptoms emerge. 1

• Clinically significant withdrawal symptoms (severe anxiety, tremor, insomnia, confusion, or any seizure activity) signal the need to slow the taper rate or pause entirely. 1

• Monitor at least monthly during the taper, with more frequent contact (weekly or biweekly) during difficult phases. 1 Assess withdrawal symptoms, mood changes, suicidal ideation, and screen for depression and substance use disorders that may emerge. 1

---

First‑Line Non‑Pharmacologic Intervention: CBT‑I

• Initiate Cognitive Behavioral Therapy for Insomnia (CBT‑I) immediately as the standard of care for chronic insomnia; it provides superior long‑term efficacy compared to medications and maintains benefits after drug discontinuation. 4, 5

• CBT‑I significantly increases benzodiazepine taper success rates and should be integrated throughout the tapering process. 1

• Core CBT‑I components include:

  • Stimulus control: Use the bed only for sleep; leave the bed if unable to fall asleep within ~20 minutes. 5
  • Sleep restriction: Limit time in bed to approximate actual sleep time plus 30 minutes. 5
  • Relaxation techniques: Progressive muscle relaxation, guided imagery, breathing exercises. 5
  • Cognitive restructuring: Modify negative beliefs about sleep (e.g., "I must have 8 hours or I'll be dysfunctional"). 5
  • Sleep hygiene: Maintain a consistent wake time every day (including weekends), avoid caffeine ≥6 hours before bedtime, eliminate screens ≥1 hour before bed, keep the bedroom quiet and temperature‑regulated. 5

• CBT‑I can be delivered via individual therapy, group sessions, telephone, web‑based modules, or self‑help books—all formats show effectiveness. 5

---

Pharmacologic Alternative to Alprazolam

Why NOT Trazodone or Mirtazapine

• Trazodone is explicitly not recommended by the American Academy of Sleep Medicine for insomnia; it yields only ~10 minutes reduction in sleep latency with no improvement in subjective sleep quality, and adverse events occur in ~75% of older adults (headache, somnolence). 4, 5

• Mirtazapine is positioned as a third‑line option for insomnia, appropriate primarily when comorbid depression or anxiety is present. 5 It requires nightly scheduled dosing (not PRN) due to its 20–40 hour half‑life and takes several days to reach steady‑state. 5 Since this patient has already tried mirtazapine, it is not the optimal choice unless depression/anxiety is a primary concern.

Recommended Alternative: Low‑Dose Doxepin

• Low‑dose doxepin 3–6 mg at bedtime is the preferred first‑line hypnotic for elderly patients with sleep‑maintenance insomnia transitioning off benzodiazepines. 5

• Efficacy: Moderate‑quality evidence shows doxepin reduces wake after sleep onset by 22–23 minutes and improves sleep efficiency, total sleep time, and sleep quality. 4, 5

• Safety profile: At hypnotic doses (3–6 mg), doxepin has minimal anticholinergic activity, no abuse potential, and no DEA scheduling. 5 This makes it especially suitable for older adults discontinuing anticholinergic agents or benzodiazepines. 5

• Dosing: Start doxepin 3 mg at bedtime; if insufficient after 1–2 weeks, increase to 6 mg. 5

Alternative Options if Doxepin Fails

• Suvorexant 10 mg (orexin‑receptor antagonist) reduces wake after sleep onset by 16–28 minutes with lower risk of cognitive and psychomotor impairment than benzodiazepine‑type agents. 5

• Ramelteon 8 mg (melatonin‑receptor agonist) improves sleep‑onset latency with no abuse potential and no withdrawal symptoms. 5

• Eszopiclone 1–2 mg (maximum 2 mg for elderly) increases total sleep time by 28–57 minutes but carries higher risk of complex sleep behaviors, falls, and cognitive impairment compared to doxepin. 5 FDA labeling limits use to ≤4 weeks. 5

---

Adjunctive Strategies to Improve Taper Success

Pharmacologic Adjuncts for Withdrawal Symptoms

• Gabapentin can mitigate withdrawal symptoms: start 100–300 mg at bedtime or three times daily, increase by 100–300 mg every 1–7 days as tolerated; adjust dose in renal insufficiency. 1

• Carbamazepine may assist discontinuation, though it can affect alprazolam metabolism. 1

• SSRIs (particularly paroxetine) may help manage underlying anxiety during tapering. 1

Patient Education and Support

• Explain that chronic benzodiazepine use can paradoxically increase breakthrough anxiety and that discontinuation will ultimately improve anxiety control. 1

• Use shared decision‑making: Explain the risks of continued use (falls, fractures, cognitive decline, dementia risk) versus benefits of discontinuation (improved psychomotor and cognitive functioning, particularly memory and daytime alertness). 1

• Establish realistic expectations: The taper will take 12–18 months minimum; pauses are normal and acceptable. 1

• Multidisciplinary support: Nurses, pharmacists, and behavioral health professionals can provide additional support via telephone, telehealth, or face‑to‑face visits. 1

---

Monitoring Requirements

• Follow up at least monthly during the taper, with more frequent contact (weekly or biweekly) during difficult phases. 1

• At each visit, assess:

  • Withdrawal symptoms (anxiety, tremor, insomnia, sweating, tachycardia, headache, confusion, seizures). 1
  • Mood changes and suicidal ideation. 1
  • Sleep parameters (sleep‑onset latency, total sleep time, nocturnal awakenings, daytime functioning). 5
  • Adverse effects of any new hypnotic (morning sedation, cognitive impairment, falls). 5

• Screen for depression, anxiety, and substance use disorders that may emerge during tapering. 1

• Advise the patient of increased overdose risk if she returns to previous doses after tolerance is lost. 1

---

When to Refer to a Specialist

• Immediate specialist referral is indicated for:
  • History of withdrawal seizures. 1
  • Unstable psychiatric comorbidities (severe depression, active suicidal ideation). 1
  • Co‑occurring substance use disorders. 1
  • Previous unsuccessful office‑based tapering attempts. 1

---

Common Pitfalls to Avoid

• Never taper too quickly: Reducing by 25% every 1–2 weeks (as sometimes recommended for short‑term users) is too aggressive for a patient on 2.5 mg for an extended period. 1 Use 10% per month instead. 1

• Never reduce by a percentage of the original dose: Always calculate reductions as a percentage of the current dose to prevent disproportionately large final decrements. 1

• Never abandon the patient: Even if tapering is unsuccessful, maintain the therapeutic relationship and consider maintenance therapy at a reduced dose as a legitimate outcome. 1

• Never substitute another benzodiazepine or Z‑drug (zolpidem, zaleplon) as these carry similar risks in older adults. 1

• Never initiate pharmacotherapy without first employing CBT‑I: Behavioral therapy provides more durable benefits than medication alone. 5

• Never combine multiple sedative agents (e.g., adding a Z‑drug to alprazolam during the taper), as this markedly increases risk of respiratory depression, cognitive impairment, and falls. 5

---

Expected Outcomes

• Successful withdrawal is typically followed by improved psychomotor and cognitive functioning, particularly in memory and daytime alertness. 1

• Improvement in anxiety symptoms and general well‑being is maintained during both the taper and follow‑up phases. 1

• Both complete discontinuation and attainment of a reduced, functionally acceptable dose are considered acceptable outcomes based on patient goals and tolerance. 1

---

Practical Implementation Summary

1. Week 1: Initiate CBT‑I (refer to therapist or provide web‑based program); educate patient about taper rationale, timeline, and withdrawal symptoms. 5, 1

2. Month 1: Begin alprazolam taper (2.5 mg → 2.25 mg); start low‑dose doxepin 3 mg at bedtime as alternative hypnotic. 5, 1

3. Months 2–18+: Continue 10% monthly dose reductions; titrate doxepin to 6 mg if needed after 1–2 weeks; monitor monthly for withdrawal symptoms, mood changes, and sleep quality. 5, 1

4. Throughout taper: Reinforce CBT‑I techniques; consider gabapentin if withdrawal symptoms emerge; pause taper for 2–4 weeks if clinically significant withdrawal occurs. 5, 1

5. Final phase: Once the smallest available alprazolam dose is reached, extend the interval between doses (e.g., every other night, then every third night) before complete discontinuation. 1